139 related articles for article (PubMed ID: 24754926)
1. Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging.
Salphati L; Shahidi-Latham S; Quiason C; Barck K; Nishimura M; Alicke B; Pang J; Carano RA; Olivero AG; Phillips HS
Drug Metab Dispos; 2014 Jul; 42(7):1110-6. PubMed ID: 24754926
[TBL] [Abstract][Full Text] [Related]
2. Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
Salphati L; Alicke B; Heffron TP; Shahidi-Latham S; Nishimura M; Cao T; Carano RA; Cheong J; Greve J; Koeppen H; Lau S; Lee LB; Nannini-Pepe M; Pang J; Plise EG; Quiason C; Rangell L; Zhang X; Gould SE; Phillips HS; Olivero AG
Drug Metab Dispos; 2016 Dec; 44(12):1881-1889. PubMed ID: 27638506
[TBL] [Abstract][Full Text] [Related]
3. Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.
Salphati L; Heffron TP; Alicke B; Nishimura M; Barck K; Carano RA; Cheong J; Edgar KA; Greve J; Kharbanda S; Koeppen H; Lau S; Lee LB; Pang J; Plise EG; Pokorny JL; Reslan HB; Sarkaria JN; Wallin JJ; Zhang X; Gould SE; Olivero AG; Phillips HS
Clin Cancer Res; 2012 Nov; 18(22):6239-48. PubMed ID: 22992516
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Salphati L; Wong H; Belvin M; Bradford D; Edgar KA; Prior WW; Sampath D; Wallin JJ
Drug Metab Dispos; 2010 Sep; 38(9):1436-42. PubMed ID: 20538720
[TBL] [Abstract][Full Text] [Related]
5. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
Folkes AJ; Ahmadi K; Alderton WK; Alix S; Baker SJ; Box G; Chuckowree IS; Clarke PA; Depledge P; Eccles SA; Friedman LS; Hayes A; Hancox TC; Kugendradas A; Lensun L; Moore P; Olivero AG; Pang J; Patel S; Pergl-Wilson GH; Raynaud FI; Robson A; Saghir N; Salphati L; Sohal S; Ultsch MH; Valenti M; Wallweber HJ; Wan NC; Wiesmann C; Workman P; Zhyvoloup A; Zvelebil MJ; Shuttleworth SJ
J Med Chem; 2008 Sep; 51(18):5522-32. PubMed ID: 18754654
[TBL] [Abstract][Full Text] [Related]
6. Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.
Becker CM; Oberoi RK; McFarren SJ; Muldoon DM; Pafundi DH; Pokorny JL; Brinkmann DH; Ohlfest JR; Sarkaria JN; Largaespada DA; Elmquist WF
Neuro Oncol; 2015 Sep; 17(9):1210-9. PubMed ID: 25972455
[TBL] [Abstract][Full Text] [Related]
7. Monitoring therapeutic monoclonal antibodies in brain tumor.
Ait-Belkacem R; Berenguer C; Villard C; Ouafik L; Figarella-Branger D; Beck A; Chinot O; Lafitte D
MAbs; 2014; 6(6):1385-93. PubMed ID: 25484065
[TBL] [Abstract][Full Text] [Related]
8. Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Salphati L; Lee LB; Pang J; Plise EG; Zhang X
Drug Metab Dispos; 2010 Sep; 38(9):1422-6. PubMed ID: 20522663
[TBL] [Abstract][Full Text] [Related]
9.
Han N; Jiang Y; Gai Y; Liu Q; Yuan L; Wang Y; Li M; Zhang Y; Lan X
Contrast Media Mol Imaging; 2019; 2019():1760184. PubMed ID: 31787861
[TBL] [Abstract][Full Text] [Related]
10. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.
Raynaud FI; Eccles SA; Patel S; Alix S; Box G; Chuckowree I; Folkes A; Gowan S; De Haven Brandon A; Di Stefano F; Hayes A; Henley AT; Lensun L; Pergl-Wilson G; Robson A; Saghir N; Zhyvoloup A; McDonald E; Sheldrake P; Shuttleworth S; Valenti M; Wan NC; Clarke PA; Workman P
Mol Cancer Ther; 2009 Jul; 8(7):1725-38. PubMed ID: 19584227
[TBL] [Abstract][Full Text] [Related]
11. The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.
Pokorny JL; Calligaris D; Gupta SK; Iyekegbe DO; Mueller D; Bakken KK; Carlson BL; Schroeder MA; Evans DL; Lou Z; Decker PA; Eckel-Passow JE; Pucci V; Ma B; Shumway SD; Elmquist WF; Agar NY; Sarkaria JN
Clin Cancer Res; 2015 Apr; 21(8):1916-24. PubMed ID: 25609063
[TBL] [Abstract][Full Text] [Related]
12. MALDI imaging and in-source decay for top-down characterization of glioblastoma.
Ait-Belkacem R; Berenguer C; Villard C; Ouafik L; Figarella-Branger D; Chinot O; Lafitte D
Proteomics; 2014 May; 14(10):1290-301. PubMed ID: 24376047
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma.
Li W; Liu Y; Yang W; Han X; Li S; Liu H; Gerweck LE; Fukumura D; Loeffler JS; Yang BB; Jain RK; Huang P
J Neurooncol; 2018 Jan; 136(1):63-71. PubMed ID: 29081036
[TBL] [Abstract][Full Text] [Related]
14. Identification of differentially expressed proteins in human glioblastoma cell lines and tumors.
Zhang R; Tremblay TL; McDermid A; Thibault P; Stanimirovic D
Glia; 2003 Apr; 42(2):194-208. PubMed ID: 12655603
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.
Avramis IA; Christodoulopoulos G; Suzuki A; Laug WE; Gonzalez-Gomez I; McNamara G; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2002 Dec; 50(6):479-89. PubMed ID: 12451475
[TBL] [Abstract][Full Text] [Related]
16. BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma.
Speranza MC; Nowicki MO; Behera P; Cho CF; Chiocca EA; Lawler SE
Sci Rep; 2016 Feb; 6():20189. PubMed ID: 26846842
[TBL] [Abstract][Full Text] [Related]
17. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models.
Bagci-Onder T; Wakimoto H; Anderegg M; Cameron C; Shah K
Cancer Res; 2011 Jan; 71(1):154-63. PubMed ID: 21084267
[TBL] [Abstract][Full Text] [Related]
18. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
[TBL] [Abstract][Full Text] [Related]
19. Protein identification by accurate mass matrix-assisted laser desorption/ionization imaging of tryptic peptides.
Schober Y; Schramm T; Spengler B; Römpp A
Rapid Commun Mass Spectrom; 2011 Sep; 25(17):2475-83. PubMed ID: 21818808
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma multiforme: Metabolic differences to peritumoral tissue and IDH-mutated gliomas revealed by mass spectrometry imaging.
Kampa JM; Kellner U; Marsching C; Ramallo Guevara C; Knappe UJ; Sahin M; Giampà M; Niehaus K; Bednarz H
Neuropathology; 2020 Dec; 40(6):546-558. PubMed ID: 32662157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]